通过调节miR-508-3pp,LncRNA DEPDC1-AS1驱动子宫内膜癌的进展
1Department of Obstetrics and Gynecology, Renhe Hospital, No. 1999, Changjiang West Road, Baoshan District, Shanghai, 200431, China.
Discover oncology
|September 26, 2025
概括
长非编码RNADEPDC1-AS1通过海绵miR-508-3p促进子宫内膜癌 (EC) 的进展,影响细胞的攻击性. DEPDC1-AS1作为潜在的预后生物标志物和EC的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 子宫内膜癌 (EC) 是一种常见的妇科恶性瘤.
- 长非编码RNA (lncRNA) DEPDC1-AS1在EC病原发生中的作用在很大程度上是未知的.
研究的目的:
- 研究DEPDC1-AS1在子宫内膜癌中的表达,预后价值和功能作用.
- 阐明DEPDC1-AS1在EC中的作用背后的分子机制.
主要方法:
- 定量实时PCR (qRT-PCR) 测量DEPDC1-AS1,miR-508-3p和SQSTM1表达在100个EC和100个增生组织中.
- 生存分析 (卡普兰-梅尔,考克斯回归) 和相关性分析 (皮尔森).
- 在体外测定 (CCK-8,Transwell) 来评估细胞增殖,迁移和入侵;双露西法酶记者测定以验证相互作用.
主要成果:
- 在EC组织和细胞系中,DEPDC1-AS1被上调,并被确定为独立的预后因素.
- 抑制DEPDC1-AS1抑制了EC细胞的增殖,迁移和入侵.
- DEPDC1-AS1海绵miR-508-3p,这种相互作用通过准SQSTM1.1,促进EC细胞的攻击性.
结论:
- DEPDC1-AS1是EC的一个有前途的预后生物标志物.
- DEPDC1-AS1通过miR-508-3p/SQSTM1轴促进EC进展,表明其作为治疗点的潜力.
相关概念视频
MicroRNAs
3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs
23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K
lncRNA - Long Non-coding RNAs
9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


